undamentalytics Newsletter
Sign in

Myomo, Inc. (MYO) stock

Add to watchlist

Add holding +

NYSE: MYO NYSE Health Care Equipment Next results ~November 9, 2026

C Fundamentals grade

Myomo, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.6

Valuation models combined (3)

Base case. Range ~$0.3–$1.6. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Myomo, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 3 selling13 purchases and 8 sales by directors and officers, last 12 monthsInsider trades
  • Funds50 adding, 42 cuttingOf 11 active managers that changed their stake, 7 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Myomo files

Where Myomo stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $43m, up 6.1% on a year earlier, slower than the 6.7% growth a quarter earlier. Free-cash-flow margin rose to -19.2% from -28.8% a year earlier. Operating margin narrowed to -27.1% from -22.8%. The diluted share count is up 5.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 5 financial-health checks. Our revenue-to-maturity cash-flow model value is $0.68 a share.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Myomo, Inc.'s trailing-twelve-month revenue grew 6.1% year on year, with a free-cash-flow margin of -19.2%. Where it stands out: days sales outstanding of 42 days ranks 21 of 118 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 29.1% while net income fell 55.6%: a 85pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Myomo, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -27.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 4.2 points on a year ago.
  • Burning cash. Free cash flow was -19.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 5.9% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 95% and a beta of 2.2 against the S&P 500.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.07 against an average estimate of -$0.10: beat by 33.9%
Revenue
$12m, up 21.3% on a year earlier
Share reaction
+21.3% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
revenue $11.5m to $12m (third quarter of 2026); revenue growth growth 10% to 15% (full year 2026)
Next report
November 9, 2026; average EPS estimate -$0.07

Myomo's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.2%
  • 1 week0.0%
  • 1 month-26.4%
  • This year+31.9%
  • 1 year+29.6%
  • 5 years-88.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$43.3M
Operating margin
-27.1%
Net margin
-33.5%
EPS (TTM, diluted)
$-0.34

Growth

Revenue growth
+6.1%
Change in growth rate
−0.5 pts
Share count change
+5.9%

Cash

Free cash flow (TTM)
-$8.3M
FCF margin
-19.2%
Stock pay % of revenue
6.4%

Earnings

Last results
August 5, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Myomo, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Myomo, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.16 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.3 ~$0.1–$0.4 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.6 ~$1.8–$6.0 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.7 ~$0.4–$0.9 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.6 ~$0.3–$1.6 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Myomo, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201720182019202020212022202320242025Now
Share price$112.50$43.20$9.03$6.73$6.84$0.51$5.01$6.44$0.91$1.20
Market value$194m$71m$20m$90m$160m$14m$148m$243m$38m$51m
+ Net debt (− = net cash)−$13m−$7m−$2m−$12m−$16m−$5m−$7m−$13m−$2m$1m
Enterprise value$181m$64m$18m$77m$144m$9m$141m$230m$36m$52m
Multiples
Price / sales 124.6x29.0x5.2x11.8x11.5x0.9x7.7x7.5x0.9x1.2x
Price / earnings ——————————
Price / free cash flow ——————————
EV / EBITDA ——————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

33 /100

Weak moat

How hard Myomo's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -63.7% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 68.2%, moving by 2.2 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -76.2%; its worst year was -461.2%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -57.6% of revenue.

  • Discipline 3 / 20

    The diluted share count rose 2790.9% over five years; stock-based pay has been a median 7.8% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $12m and EPS of −$0.07 (range −$0.08 to −$0.07) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.31 +16% $46m +11%
Next −$0.22 +28% $51m +12%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.1% on 90 days ago. In the last 30 days, 2 analysts raised Myomo, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Myomo, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.31 Current fiscal year, 60 days ago: −$0.32 Current fiscal year, 30 days ago: −$0.32 Current fiscal year, 7 days ago: −$0.30 Current fiscal year, Now: −$0.31 −$0.31 Next fiscal year, 90 days ago: −$0.25 Next fiscal year, 60 days ago: −$0.25 Next fiscal year, 30 days ago: −$0.25 Next fiscal year, 7 days ago: −$0.23 Next fiscal year, Now: −$0.22 −$0.22

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.31−$0.25
60 days ago −$0.32−$0.25
30 days ago −$0.32−$0.25
7 days ago −$0.30−$0.23
Now −$0.31−$0.22

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.10 −$0.07 +33.9%
Mar 2026 −$0.12 −$0.09 +20.9%
Dec 2025 −$0.09 −$0.09 −0.2%
Sept 2025 −$0.11 −$0.09 +16.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • revenue growth full year 2026 10% growth to 15% growth Raised
    “We anticipate continued progress on these initiatives and as a result are raising the revenue guidance to approximately 10-15% growth over the prior year.” source
  • full year revenue guidance full year 2026 $45m to $47m Raised
    “We are raising our full year revenue guidance to $45 million to $47 million.” source
  • revenue third quarter of 2026 $11.5m to $12m
    “We expect third quarter 2026 revenue to be in the range of $11.5 million to $12.0 million, up 14% to 19% year-over-year.” source
  • cash burn second half of the year —
    “we expect cash burn to be less than $2 million during the second half of the year” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026145

Counts of recommendations published by analysts covering Myomo, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.0%
of tradable shares
Days to cover
3.12
at average volume
Short interest, 1 month
−11%
to October 15, 2026
Held by institutions
38%
of shares
Held by insiders
10.4%
of shares
Employees
194
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +29.6%

$0.93 on October 31, 2025 to $1.20

ThenNowEffect
Revenue (last 12 months) $41m $43m +6.1%
P/S multiple 0.9x 1.2x +29.3%
Share count 40m 42m −5.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MYO+2%−93%+880%+29%−86%+32%
Industry peers (median)−9%−37%−9%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MYO58%33%67%42%17%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MYO−62%−95%−43%−46%−90%−42%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 12, 2017: 100% from June 19, 2017 to January 12, 2023. Getting back needed a 143647% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.64 – $1.86
From 52-week high
−35.5%
vs 50-day average
−14.7%
vs 200-day average
+11.2%
Volatility (1 year)
95%
Beta vs S&P 500
2.17

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±21.1%
After a week
6 up, 6 down
typical move ±21.8%
After a month
5 up, 7 down
typical move ±28.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +21.3% −0.4% +40.7% +29.6%
May 7, 2026 −2.9% +0.5% +4.1% +50.1%
March 9, 2026 −15.7% +0.7% −7.6% −15.1%
November 10, 2025 −0.5% +1.8% −9.8% +25.3%
August 11, 2025 −41.0% +0.9% −38.8% −52.3%
May 7, 2025 −29.6% +1.1% −31.9% −37.5%
March 10, 2025 +27.6% −3.5% +18.3% −3.5%
November 6, 2024 +26.8% +3.3% +19.2% +52.0%
August 6, 2024 −10.8% +0.2% −6.1% −7.6%
July 8, 2024 +62.0% +0.2% +74.2% +46.3%
May 8, 2024 −1.7% +0.6% +4.4% −6.4%
March 7, 2024 −13.3% +0.4% −6.5% −14.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Myomo, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Myomo, Inc.
$10M $20M $30M $40M $50M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $18.5M Revenue (TTM), FY23 Q4: $19.2M Revenue (TTM), FY24 Q1: $19.5M Revenue (TTM), FY24 Q2: $21.1M Revenue (TTM), FY24 Q3: $25.2M Revenue (TTM), FY24 Q4: $32.6M Revenue (TTM), FY25 Q1: $38.6M Revenue (TTM), FY25 Q2: $40.8M Revenue (TTM), FY25 Q3: $41.6M Revenue (TTM), FY25 Q4: $40.9M Revenue (TTM), FY26 Q1: $41.2M Revenue (TTM), FY26 Q2: $43.3M $43.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $18.5M
FY23 Q4 $19.2M
FY24 Q1 $19.5M
FY24 Q2 $21.1M
FY24 Q3 $25.2M
FY24 Q4 $32.6M
FY25 Q1 $38.6M
FY25 Q2 $40.8M
FY25 Q3 $41.6M
FY25 Q4 $40.9M
FY26 Q1 $41.2M
FY26 Q2 $43.3M
Revenue growth, TTM YoY Myomo, Inc.
0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 19.2% Revenue growth, TTM YoY, FY23 Q4: 23.7% Revenue growth, TTM YoY, FY24 Q1: 29.2% Revenue growth, TTM YoY, FY24 Q2: 21.2% Revenue growth, TTM YoY, FY24 Q3: 36.2% Revenue growth, TTM YoY, FY24 Q4: 69.2% Revenue growth, TTM YoY, FY25 Q1: 97.6% Revenue growth, TTM YoY, FY25 Q2: 93.1% Revenue growth, TTM YoY, FY25 Q3: 65.0% Revenue growth, TTM YoY, FY25 Q4: 25.7% Revenue growth, TTM YoY, FY26 Q1: 6.7% Revenue growth, TTM YoY, FY26 Q2: 6.1% 6.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 19.2%
FY23 Q4 23.7%
FY24 Q1 29.2%
FY24 Q2 21.2%
FY24 Q3 36.2%
FY24 Q4 69.2%
FY25 Q1 97.6%
FY25 Q2 93.1%
FY25 Q3 65.0%
FY25 Q4 25.7%
FY26 Q1 6.7%
FY26 Q2 6.1%
Operating margin (TTM) Myomo, Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -43.3% Operating margin (TTM), FY23 Q4: -42.8% Operating margin (TTM), FY24 Q1: -48.3% Operating margin (TTM), FY24 Q2: -44.8% Operating margin (TTM), FY24 Q3: -33.3% Operating margin (TTM), FY24 Q4: -19.1% Operating margin (TTM), FY25 Q1: -15.1% Operating margin (TTM), FY25 Q2: -22.8% Operating margin (TTM), FY25 Q3: -28.5% Operating margin (TTM), FY25 Q4: -35.2% Operating margin (TTM), FY26 Q1: -34.1% Operating margin (TTM), FY26 Q2: -27.1% -27.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -43.3%
FY23 Q4 -42.8%
FY24 Q1 -48.3%
FY24 Q2 -44.8%
FY24 Q3 -33.3%
FY24 Q4 -19.1%
FY25 Q1 -15.1%
FY25 Q2 -22.8%
FY25 Q3 -28.5%
FY25 Q4 -35.2%
FY26 Q1 -34.1%
FY26 Q2 -27.1%
FCF margin (TTM) Myomo, Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -34.5% FCF margin (TTM), FY23 Q4: -32.8% FCF margin (TTM), FY24 Q1: -39.7% FCF margin (TTM), FY24 Q2: -45.0% FCF margin (TTM), FY24 Q3: -37.8% FCF margin (TTM), FY24 Q4: -14.3% FCF margin (TTM), FY25 Q1: -12.1% FCF margin (TTM), FY25 Q2: -28.8% FCF margin (TTM), FY25 Q3: -33.3% FCF margin (TTM), FY25 Q4: -39.7% FCF margin (TTM), FY26 Q1: -37.4% FCF margin (TTM), FY26 Q2: -19.2% -19.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -34.5%
FY23 Q4 -32.8%
FY24 Q1 -39.7%
FY24 Q2 -45.0%
FY24 Q3 -37.8%
FY24 Q4 -14.3%
FY25 Q1 -12.1%
FY25 Q2 -28.8%
FY25 Q3 -33.3%
FY25 Q4 -39.7%
FY26 Q1 -37.4%
FY26 Q2 -19.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 2 2 4 8 14 16 19 33 41 43
Gross profit 1 1 2 2 5 10 10 13 23 27 30
EBITDA −3 −7 −10 −11 −10 −10 −10 −8 −6 −14 −11
Operating income −3 −7 −11 −11 −11 −10 −11 −8 −6 −14 −12
Net income −4 −12 −10 −11 −12 −10 −11 −8 −6 −16 −15
Diluted EPS −$2.58 −$7.33 −$6.29 −$5.20 −$0.92 −$0.47 −$0.38 −$0.28 −$0.16 −$0.37 −$0.34
Growth (year on year)
Revenue — +41.3% +56.8% +57.0% +97.6% +82.7% +12.3% +23.7% +69.2% +25.7% +6.1%
Margins
Gross margin 74.4% 67.6% 70.2% 63.0% 65.7% 74.4% 65.9% 68.5% 71.2% 65.7% 68.4%
EBITDA margin −296.1% −419.3% −427.9% −278.8% −137.1% −73.0% −67.4% −41.9% −18.4% −33.1% −24.3%
Operating margin −296.8% −420.1% −430.8% −281.3% −138.5% −74.1% −68.6% −42.8% −19.1% −35.2% −27.1%
Net margin −327.8% −776.0% −422.1% −279.1% −152.5% −74.9% −68.9% −42.3% −19.0% −38.1% −33.5%
Free-cash-flow margin −290.5% −399.0% −398.2% −270.8% −119.7% −71.3% −66.5% −32.8% −14.3% −39.7% −19.2%
Cash flow
Cash from operations −3 −6 −10 −10 −9 −10 −10 −6 −3 −15 −7
Capital spending 0 0 0 0 0 0 0 0 1 2 1
Free cash flow −3 −6 −10 −10 −9 −10 −10 −6 −5 −16 −8
Stock-based pay 0 0 1 1 1 1 1 1 1 2 3
Free cash flow after stock pay −3 −6 −11 −11 −10 −11 −12 −7 −6 −18 −11
Balance sheet
Cash 1 13 7 4 12 16 5 7 24 14 11
Total debt 2 — 0 3 — 0 0 0 11 13 13
Net debt (negative = net cash) 1 −13 −7 −2 −12 −16 −5 −7 −13 −2 1
Diluted shares 2m 2m 2m 2m 13m 23m 28m 29m 38m 42m 42m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $35m
Short-term assets $25mLonger-term assets $11m
What it owes, and who funded it · $35m
Short-term liabilities $11mLonger-term liabilities $19mShareholders' equity $6m
  • Short-term assets cover short-term liabilities $25m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $25m short-term assets against $19m of longer-dated liabilities.
  • More cash than debt $11m of cash against $12m of debt.
  • Debt below 40% of shareholders' equity Debt is 205% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$7m of operating cash flow against $12m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Myomo, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+5.9%
year over year
R&D spending
15.0%
of revenue
Days sales outstanding
42 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated MYO SNWV TLSI KRMD CLPT SENS Median
Revenue, last 12 months $43m $44m $45m $45m $45m $49m $99m
Revenue growth, last 12 months 6.1% 12.7% 25.2% 22.4% 32.5% 90.6% 9.2%
Revenue growth, 3-year average 35.4% 34.4% 45.1% 15.3% 26.8% 38.0% 13.5%
Revenue growth, latest quarter 21.3% −3.1% 1.7% 18.2% 36.3% 117.8% 10.2%
Gross margin 68.4% 76.3% 85.8% 62.4% 61.4% 54.9% 61.2%
Operating margin −27.1% 3.4% −67.7% −3.7% −70.6% −223.2% −8.5%
Operating margin, 3-year average −31.6% 7.0% −122.3% −13.3% −66.2% −261.7% −17.9%
Net margin −33.5% 34.7% −62.6% −4.0% −79.4% −225.3% −12.0%
Cash from operations / revenue −16.4% 11.9% −50.6% 3.1% −103.6% −197.6% −1.9%
Free-cash-flow margin −19.2% 9.6% −51.6% 1.6% −105.9% −199.5% −3.9%
Free-cash-flow margin, 3-year average −31.0% −0.8% −119.5% −2.7% −58.5% −230.3% −7.0%
Stock pay / revenue 6.4% 13.4% 23.6% 6.1% 18.4% 23.2% 6.1%
Change in share count 5.9% 78.4% 73.8% 2.5% 6.7% −2.8% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 6.1% 9.1% 76 of 129
Change in growth rate Growth -0.5pp -0.6pp 62 of 129
Gross margin Profitability 68.4% 61.9% 46 of 123
Operating margin Profitability -27.1% -8.3% 79 of 132
Net margin Profitability -33.5% -12.0% 80 of 133
Free-cash-flow margin Cash generation -19.2% -3.4% 80 of 128
Stock pay as % of revenue Cash generation 6.4% 6.1% 65 of 123
Long-term debt as % of assets Balance sheet 32.6% 24.2% 60 of 87
Change in share count Balance sheet 5.9% 3.3% 76 of 115
Days sales outstanding Balance sheet 42 days 57 days 21 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$12.7M
Institutions reporting
80
Shares held vs prior quarter
▼ 4.8%
Positions opened / closed
24 / 22

Top buyers and sellers, Q2 2026: 50 institutions bought and 42 sold ; the biggest buyer was AQR Capital Management LLC (+609K shares) and the biggest seller Blackrock, Inc (−1.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Rosalind Advisors, Inc. $3.8M 3.6M 29.9% ▼ 5.4%
Vanguard Capital Management LLC $1.7M 1.6M 13.4% ▲ 43.0%
AQR Capital Management LLC $965,397 928K 7.6% ▲ 191.0%
Jefferies Financial Group Inc. $732,446 704K 5.8% 0.0%
Jane Street Group, LLC $620,206 596K 4.9% New
Clearstead Advisors, LLC $442,635 426K 3.5% 0.0%
UBS Group AG $430,227 414K 3.4% ▲ 32.7%
Geode Capital Management, LLC $358,309 344K 2.8% ▼ 59.9%
LPL Financial LLC $320,320 308K 2.5% ▲ 0.7%
Palumbo Wealth Management LLC $311,768 300K 2.5% New
Gsa Capital Partners LLP $283,000 272K 2.2% ▲ 22.8%
Millennium Management LLC $282,146 271K 2.2% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Myomo, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $442,540 13 trades by 4 insiders, last 12 months Insider sales History → $230,903 8 trades by 3 insiders · 0% under pre-set plans
Net ▲ $211,637 net buying
Insider Date Trade Shares Price Value
Kovelman Harry Chief Medical Officer September 11, 2026 Sell 15,844 $1.27 $20,136
Kovelman Harry Chief Medical Officer September 11, 2026 Sell 15,488 $1.27 $19,670
Morris Milton Mayo Director September 2, 2026 Sell 15,000 $1.41 $21,150
Kovelman Harry Chief Medical Officer August 20, 2026 Sell 17,250 $1.73 $29,842
Kovelman Harry Chief Medical Officer August 20, 2026 Sell 17,500 $1.73 $30,275
Kirk Thomas F Director June 5, 2026 Buy 40,002 $1.27 $50,803
Kovelman Harry Chief Medical Officer May 28, 2026 Sell 11,536 $1.02 $11,767
Kirk Thomas F Director May 28, 2026 Buy 25,000 $0.99 $24,750
Kovelman Harry Chief Medical Officer May 27, 2026 Sell 20,464 $1.00 $20,464
Kirk Thomas F Director May 18, 2026 Buy 43,401 $0.91 $39,495
Manko Joseph M. Jr. Director May 15, 2026 Buy 30,367 $0.89 $27,027
Kirk Thomas F Director May 15, 2026 Buy 31,605 $0.91 $28,761

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 7, 2026
  • March 9, 2026
  • November 10, 2025
  • August 11, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Myomo, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Myomo, Inc. in brief

What does Myomo, Inc. do?
Myomo, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Myomo, Inc.'s stock ticker?
Myomo, Inc. trades under the ticker MYO on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Myomo, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Myomo, Inc. reported revenue of $43.3M, 6.1% higher than a year earlier, according to its SEC filings.
What is Myomo, Inc.'s free cash flow?
Myomo, Inc.'s free-cash-flow margin is -19.2% of revenue over the trailing twelve months, ranking 80 of the 128 health care equipment companies we cover.
Who are Myomo, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Rosalind Advisors, Inc., Vanguard Capital Management LLC and AQR Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Myomo, Inc.'s market cap?
On November 2, 2026, Myomo, Inc.'s market capitalisation was about $50.8M and net debt of $1.4M. Market figures come from third-party market data and may be delayed.
How much debt does Myomo, Inc. have?
Myomo, Inc.'s debt-to-equity ratio is 205.5%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Myomo, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Myomo, Inc. are Sanuwave Health, Inc., Trisalus Life Sciences, Inc., Koru Medical Systems, Inc., Clearpoint Neuro, Inc. and Senseonics Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Myomo, Inc.'s.
Are insiders buying or selling Myomo, Inc. stock?
Over the last 12 months, Myomo, Inc.'s directors and officers reported 13 open-market purchases and 8 sales on Form 4. The insider trading page charts every trade.
When is Myomo, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Myomo, Inc. announces its own schedule.